The results of the PEGASUS-TIMI 54 (Long-Term Use of Ticagrelor in patients with Prior Myocardial Infarction) trial were presented to a capacity audience at the opening session of the March 2015 American College of Cardiology meeting. But after hearing the much anticipated results and reading the simultaneously published manuscript we’re left wondering if PEGASUS is a landmark clinical trial or simply a trial that validates what we have known for years.1
To... Read More
The appropriate duration of dual antiplatelet therapy (DAPT) for patients following placement of a drug-eluting stent (DES) remains controversial.1 Many clinicians have pushed for prolonged DAPT — beyond 12 months — on the assumption that extended therapy reduces recurrent cardiovascular (CV) events. However, the benefits and harms of extended DAPT therapy are unclear and many health systems won’t authorize it. Does the Dual Antiplatelet Therapy (DAPT) study provide... Read More
Saving time and enhancing patient safety can be had by promoting a 90 day fill cycle when appropriate. Increased safety because we are filling about 4 times per year vs 12 times. Thus saving time for more MTM and patient couselling.
A second practice of keeping medications in the original container we help to decrease common filling errors of quantity counts and labels on the wrong vial.